Navigation Links
Onyx Pharmaceuticals Reports 2008 First Quarter Results
Date:5/6/2008

the meaning of the federal securities laws. These forward-looking statements include without limitation, statements regarding sales trends and commercial activities and the timing, progress and results of clinical development, regulatory filings and actions. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated. Reference should be made to Onyx's Annual Report on Form 10-K for the year ended December 31, 2007, filed with the Securities and Exchange Commission under the heading "Risk Factors" for a more detailed description of such factors, as well as the company's subsequent quarterly reports on Form 10-Q. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release. Onyx undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.

(See attached tables.)

ONYX PHARMACEUTICALS, INC.

SUMMARY FINANCIAL INFORMATION

CONDENSED STATEMENTS OF OPERATIONS

(In thousands, except per share amounts)

(unaudited)

Three Months Ended Mar. 31,

---------------------------

2008 2007

------- -------

Net revenue from unconsolidated joint

business $37,738 $3,025

Operating expenses:

Research and development (1) 7,438 5,534

Selling, general and administrative (1) 19,844
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... July 11, 2014 , Not for ... into or from any jurisdiction where to do so would ... Shire plc ("Shire" or the "Company") (LSE: SHP, ... afternoon.  Shire confirms it has held a meeting with representatives ... Shire without the prior agreement or approval of AbbVie. ...
(Date:7/11/2014)... , July 11, 2014 /CNW/ - Sunovion Pharmaceuticals ... APTIOM TM (eslicarbazepine acetate) for use as a ... in patients with epilepsy who are not satisfactorily controlled ... for use in patients under 18 years of age. ... common neurological disorders and according to Epilepsy Canada, it ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Product ... in very low abundance and are often “lost ... and time-consuming. , Join presenters Dr. Rowel Tobias, ... Dr. John Anders, Head of Quality at Nanotherapeutics, ... approach that can speed detection and quantitation while ...
(Date:7/10/2014)... 2014 Unraveling life’s mysteries can intrigue, ... Archer Family purchased a DNA test to ... up with a lifetime of memories, sharing, and closeness. ... members’ DNA genuinely brought the family closer together. ... into genetic history and prior to taking the ...
Breaking Biology Technology:Shire plc - Statement re: Media Speculation 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5
... Helena Rojas to Director of Global Business Development Operations , ... ... Ltd., a leading provider of multilingual localization, testing and outsourced software ... to Vice President of Global Business Development and Helena Rojas to ...
... China, March 4 /PRNewswire-Asia-FirstCall/ -- Mindray Medical,International Limited ... manufacturer and,marketer of medical devices worldwide, today announced ... Officer of the Company effective as of May ... step down from the role of Chief,Financial Officer ...
... 4 The Healthcare practice at Frost ... 2009 Quarterly Analyst Briefing Presentation on the North ... March 5, 2009 at 10:00 a.m. PST. (Logo: ... growth and is experiencing several notable trends, such ...
Cached Biology Technology:Localization and Translation Leader CSOFT International Ltd. Recognizes Efforts of Two Key Members of its Business Development Team 2Localization and Translation Leader CSOFT International Ltd. Recognizes Efforts of Two Key Members of its Business Development Team 3Mindray Appoints Mr. Ronald Ede as Chief Financial Officer 2Mindray Appoints Mr. Ronald Ede as Chief Financial Officer 3Frost & Sullivan's Biopharmaceuticals Market Briefing to Address the Use of Embryonic Stem Cells 2
(Date:7/11/2014)... When researchers at the National Institute of Standards ... do their work more effectively, they often prove ... Such was the case recently for M. Lorna ... in the growing specialization of glycomics. Glycomics is ... called glycans that are attached to proteins and ...
(Date:7/11/2014)... University, Sweden, have explored two different ways that ... leading to the formation of oxygen molecules in ... the scientific journal Nature Communications . , ... synthetic catalysts for water oxidation, which are key ... direct storage of solar energy in fuels like ...
(Date:7/11/2014)... evidence that under the normal circumstances, astrocytes ... maintain neuronal environment, and exhibit therapeutic and ... disease. Previous studies have found that nerve ... chemical induction have reduced viability, which produces ... Xiaodong Yuan, Kailuan General Hospital, Hebei United ...
Breaking Biology News(10 mins):Molecular snapshots of oxygen formation in photosynthesis 2
... with colleagues from the Botswana National Museum shed new ... to southern Africa and from where. A domestic cow ... from a site at Toteng, located in the Kalahari ... Accelerator Mass Spectrometry (AMS) radiocarbon technique, provides the oldest ...
... found that the two primary areas of the human ... cortex used in higher-level thought undergoes more extensive changes ... such as heartbeat, breathing and balance. Their work, based ... of human and chimpanzee brains, also shows that the ...
... first time used gene therapy to successfully treat heart ... model that is genetically susceptible to a human muscular ... journal Circulation, the authors say that this is the ... the body. , "Previous attempts at systemic gene therapy ...
Cached Biology News:Human cerebellum and cortex age in very different ways 2Gene therapy reverses genetic mutation responsible for heart failure in muscular dystrophy 2Gene therapy reverses genetic mutation responsible for heart failure in muscular dystrophy 3Gene therapy reverses genetic mutation responsible for heart failure in muscular dystrophy 4
These 22x40mm rectangular No.1 Corning cover glasses are made from No. 0211 zinc titania glass and are 0.16 to 0.19mm thick. • Approx. Pcs Oz : 73...
The model 55D Rocking Shaker provides the same Reliable quality as the 55S, but double the value. The 55D gives you an additional platform with a height of 3.25 in....
... rolled steel with stove enamel coated (RAL 7035 ... Front, back and side windows ... lamps Internal adjustable tempered glass shelf ... Lighting 600 lux ...
... Shaker provides the exact agitation needed ... very slow to fast speed and ... a gentle wave motion that lifts ... membranes to achieve faster, more uniform ...
Biology Products: